Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Namkyoung Kim"'
Autor:
Sooin Kim, Sanggil Kim, Sangji Kim, Namkyoung Kim, Sang Won Lee, Hanbin Yi, Seungeun Lee, Taebo Sim, Yongseok Kwon, Hyun Soo Lee
Publikováno v:
Advanced Science, Vol 11, Iss 4, Pp n/a-n/a (2024)
Abstract Chemically modified proteins have diverse applications; however, conventional chemo‐selective methods often yield heterogeneously labeled products. To address this limitation, site‐specific protein labeling holds significant potential, d
Externí odkaz:
https://doaj.org/article/acaa5b2d67134798af040828cb36a7f3
Autor:
Namkyoung Kim, Injae Shin, Younghoon Kim, Eunhye Jeon, Jiwon Lee, Chaeyoung Lee, Yunju Nam, Sumin Lee, Eunhye Ju, Chan Kim, Woolim Son, SeongShick Ryu, Minjoo Ko, Taebo Sim
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
RAS mutants are involved in approximately 30% of all human cancers and have been regarded as undruggable targets owing to relatively smooth protein surface and obscure binding pockets. In our previous study, we have demonstrated that GNF-7, a multi-t
Externí odkaz:
https://doaj.org/article/ab077dce29e646abaf028b086d8ff2d9
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Inhibitors of tropomyosin-related kinases (TRKs) display remarkable outcomes in the regression of cancers harboring the Neurotrophin Receptors Tyrosine Kinase (NTRK) fusion gene. As a result, TRKs have become attractive targets in anti-cancer drug di
Externí odkaz:
https://doaj.org/article/b6edea554d2d45d4913285d4f8959b23
Autor:
SeongShick Ryu, Jung-Eun Park, Young Jin Ham, Daniel C. Lim, Nicholas P. Kwiatkowski, Do-Hee Kim, Debabrata Bhunia, Nam Doo Kim, Michael B. Yaffe, Woolim Son, Namkyoung Kim, Tae-Ik Choi, Puspanjali Swain, Cheol-Hee Kim, Jin-Young Lee, Nathanael S. Gray, Kyung S. Lee, Taebo Sim
Publikováno v:
Journal of Medicinal Chemistry. 65:1915-1932
The polo-box domain (PBD) of Plk1 is a promising target for cancer therapeutics. We designed and synthesized novel phosphorylated macrocyclic peptidomimetics targeting PBD based on acyclic phosphopeptide PMQSpTPL. The inhibitory activities of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::089bc18950a08c65b0ca874704a3e073
https://doi.org/10.1021/acs.jmedchem.1c01359
https://doi.org/10.1021/acs.jmedchem.1c01359
Publikováno v:
IEICE Transactions on Electronics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a01b9c5a9a9b9c6813e06e13bab21b95
https://doi.org/10.1587/transele.2023mms0001
https://doi.org/10.1587/transele.2023mms0001
Autor:
Yunju Nam, Chan Kim, Junghee Han, SeongShick Ryu, Hanna Cho, Chiman Song, Nam Doo Kim, Namkyoung Kim, Taebo Sim
Publikováno v:
Cancers; Volume 15; Issue 1; Pages: 143
c-KIT is a promising therapeutic target against gastrointestinal stromal tumor (GIST). In order to identify novel c-KIT inhibitors capable of overcoming imatinib resistance, we synthesized 31 novel thiazolo[5,4-b]pyridine derivatives and performed SA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e8cdc077e43089605d491e4ff37a981
Autor:
Younghoon Kim, Christina Seo, Eunhye Jeon, Inchul You, Kyubin Hwang, Namkyoung Kim, Ha-Soon Choi, Stephen M. Hinshaw, Nathanael S. Gray, Taebo Sim
Chemically induced protein degradation is a powerful strategy for perturbing cellular biochemistry. The predominant mechanism of action for protein degrader drugs involves induced proximity between the cellular ubiquitin conjugation machinery and the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2b0d1e8e364fb54308433ab122b67db
https://doi.org/10.1101/2022.12.17.520883
https://doi.org/10.1101/2022.12.17.520883
Autor:
Yunju, Nam, Chan, Kim, Junghee, Han, SeongShick, Ryu, Hanna, Cho, Chiman, Song, Nam Doo, Kim, Namkyoung, Kim, Taebo, Sim
Publikováno v:
Cancers. 15(1)
c-KIT is a promising therapeutic target against gastrointestinal stromal tumor (GIST). In order to identify novel c-KIT inhibitors capable of overcoming imatinib resistance, we synthesized 31 novel thiazolo[5,4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9dce576a2c7a63c9335d44effb5dbd5b
https://pubmed.ncbi.nlm.nih.gov/36612139
https://pubmed.ncbi.nlm.nih.gov/36612139
Autor:
Sumin Lim, Seulgi Choi, Ju-Kyung Lee, Eunhyun Choi, Sungwon Lee, Kwangwoo Chun, Myoungki Baek, Jiyeon Park, Jihyun Kim, Areum Kang, Younghoon Kim, Namkyoung Kim, Byoungchul Cho, Taebo Sim, Koo Lee
Publikováno v:
Cancer Research. 83:4006-4006
Targeting mutated EGFR is a clinically validated approach for tackling non-small cell lung cancer (NSCLC). Approximately 20% of patients with advanced NSCLC harbor an EGFR mutation. Osimertinib is a 3rd-generation oral EGFR-TKI targeting the EGFR sen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15f72a6186ee7bbaf4d96c8c17ef062d
https://doi.org/10.1158/1538-7445.am2023-4006
https://doi.org/10.1158/1538-7445.am2023-4006